Dawei Xuan

VP of Clinical Pharmacology at Erasca

Dawei serves as Erasca’s vice president of clinical pharmacology, providing over 20 years of experience in drug discovery and development. He joined Erasca from Turning Point Therapeutics (TPTX), where he was vice president of clinical pharmacology and a member of the leadership team. He was responsible for overall strategy and execution of clinical pharmacology plans to support the pipeline at TPTX, where he helped advance repotrectinib into a registrational trial and achieve FDA breakthrough therapy designation for the treatment of patients with TKI-naïve ROS1-positive metastatic non-small cell lung cancer. Prior to TPTX, Dawei worked at Pfizer for 17 years where he held roles of increasing responsibility, most recently as senior director of clinical pharmacology in the Early Oncology Development and Clinical Research (EODCR) organization. During his tenure at Pfizer, he worked on numerous investigational drugs across small molecules, large molecules, antibody drug conjugates and bispecific antibodies. He contributed to the discovery and development of three marketed medicines, including Eliquis®, Inspra® and Ibrance®. Earlier in his career, he worked for nine years in clinical pharmacokinetics and pharmacodynamics of antimicrobial agents at the Center for Anti-infective Research and Development at Hartford Hospital.

Dawei earned his Ph.D. in pharmaceutical sciences from the University of Connecticut and his B.S. in pharmaceutical sciences from Peking University Health Science Center.

Links

Previous companies

Pfizer logo

Timeline

  • VP of Clinical Pharmacology

    Current role

View in org chart